Johns Hopkins researchers discover genetic volume control that delays Parkinson's onset

Scientists at Johns Hopkins University School of Medicine have found a clever way to turn down the creation of a harmful protein linked to Parkinson's right at its genetic source, creating a promising new path to delay or even stop the condition from starting. The research, published in the medical journal Brain, centers on a protein called alpha-synuclein, which is deeply involved in Parkinson's. When alpha-synuclein works as it should, it helps nerve cells in the brain talk to one another. Problems start when the body makes far too much of it or when the protein loses its normal shape. When that happens, the protein sticks together to form dense, damaging lumps known as Lewy bodies. These sticky lumps build up inside the specific brain cells that produce dopamine in the midbrain, leading to cell death, swelling in the brain, and the gradual movement difficulties associated with the condition. For a long time, researchers have known that the gene responsible for making alpha-synuclein, called SNCA, is the biggest single genetic risk factor for non-inherited Parkinson's. However, finding a safe way to turn down the amount of this protein without accidentally turning off essential brain functions has been extremely difficult. Instead of trying to disable the gene itself, the team at Johns Hopkins looked at a hidden genetic switch located in a section of non-coding DNA. This special area is called an enhancer, and it sits inside a non-coding segment of DNA within the SNCA gene, specifically about 37 kilobases down from where the gene starts reading its instructions. Earlier work showed that this particular enhancer, named SncaEnh+37, functions just like a local volume dial that operates almost exclusively inside the dopamine-producing cells of the midbrain. Using the CRISPR gene-editing tool, the research team created mice that were missing this 2.76-kilobase enhancer sequence. To see exactly how well this genetic dial could be turned down, they compared mice carrying two normal copies of the enhancer, mice with just one copy, and mice with no copies at all. Using high-powered single-molecule imaging, the researchers proved that removing this enhancer noticeably turned down SNCA gene activity specifically inside midbrain dopamine neurons. This directly reduced the amount of raw protein available to form those dangerous clumps. To discover whether turning down this genetic switch provided real protection against Parkinson's symptoms, the team injected synthetic alpha-synuclein seeds directly into the brains of the mice. These lab-made seeds act like a spark, causing healthy alpha-synuclein proteins to misfold and triggering a domino effect of damage throughout the brain. Mice that still had their original enhancers went on to develop serious movement problems over time. When scientists examined their brains, they found widespread loss of nerve cells, large build-ups of Lewy bodies in a brain region called the substantia nigra, and severe brain inflammation caused by overactive immune cells called glia. Mice missing the SncaEnh+37 enhancer showed remarkable protection. In physical movement tests that measured physical grip strength, balance on a spinning rod, and movement speed climbing down a vertical pole, the mice without the enhancer performed almost like completely healthy animals. Checks on their brain tissue confirmed a massive decrease in Lewy body formation, remarkably healthy dopamine neurons, and very low levels of brain inflammation. The true strength of this discovery is its incredible precision. Turning off the entire gene across the whole body can ruin normal brain cell communication, but targeting a switch that only works in specific cells allows scientists to selectively lower protein production exclusively where it causes damage. This targeted approach to tuning down gene activity opens up an exciting direction for future treatments. By designing gene therapies or targeted medicines that focus on the switches controlling disease-causing genes, it might one day be possible to lower risk ahead of time and halt the progression of Parkinson's before permanent cell damage occurs.